Bio-Rad Laboratories, Inc.
BIOB
NYSE
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -14.58% | 6.16% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -14.58% | 6.16% | |||
| Cost of Revenue | -18.86% | 12.31% | |||
| Gross Profit | -10.27% | 0.58% | |||
| SG&A Expenses | -2.25% | 6.42% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.67% | 7.98% | |||
| Operating Income | -44.55% | -9.56% | |||
| Income Before Tax | -174.24% | 315.54% | |||
| Income Tax Expenses | -177.77% | 334.53% | |||
| Earnings from Continuing Operations | -173.21% | 310.59% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -173.21% | 310.59% | |||
| EBIT | -44.55% | -9.56% | |||
| EBITDA | -27.88% | -7.31% | |||
| EPS Basic | -173.26% | 310.17% | |||
| Normalized Basic EPS | -43.92% | 14.00% | |||
| EPS Diluted | -173.37% | 309.83% | |||
| Normalized Diluted EPS | -43.84% | 13.85% | |||
| Average Basic Shares Outstanding | -0.07% | 0.20% | |||
| Average Diluted Shares Outstanding | -0.20% | 0.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||